Price0.68%   +5.15

Regeneron Pharmaceuticals (REGN) Latest News

Dec-01-22 08:46AM Regeneron's (REGN) sBLA for Evkeeza Gets FDA Priority ReviewZacks Investment Research
06:20AM Should Goldman Sachs Equal Weight U.S. Large Cap Equity ETF (GSEW) Be on Your Investing Radar?Zacks Investment Research
Nov-30-22 05:35AM 2 Market-Beating Stocks That Can Continue Rising in 2023The Motley Fool
Nov-25-22 09:13AM Regeneron (REGN) Outperforms YTD: What's in Store for 2023?Zacks Investment Research
Nov-23-22 12:18PM Biotech Stock Roundup: CTMX Surges on REGN's Deal, APLS Up on Regulatory UpdateZacks Investment Research
10:41AM Regeneron's (REGN) Libtayo Gets EC Nod for Cervical CancerZacks Investment Research
Nov-18-22 01:18AM CytomX (CTMX) Stock Surges on Oncology Deal With RegeneronZacks Investment Research
Nov-14-22 10:10AM Bayer (BAYRY) Eylea Label Extension Gets CHMP Positive OpinionZacks Investment Research
07:43AM Sanofi (SNY), Regeneron Dupixent Gets CHMP Nod for Skin DiseaseZacks Investment Research
Nov-12-22 10:15AM 2 Top Biotech Stocks to Buy in NovemberThe Motley Fool
Nov-10-22 02:17AM Kodiak Sciences' (KOD) Q3 Earnings Beat, Eye Candidate in FocusZacks Investment Research
Nov-09-22 12:35PM Biotech Stock Roundup: REGN, AMGN, MRNA's Q3 Earnings, VERV Down on UpdateZacks Investment Research
10:43AM Regeneron (REGN) Gets FDA Nod for Libtayo's Label ExpansionZacks Investment Research
Nov-08-22 10:40AM Bayer's (BAYRY) Q3 Earnings Miss Estimates, Revenues TopZacks Investment Research
Nov-01-22 10:27AM Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022Benzinga
Oct-31-22 03:43AM Top Stock Reports for Exxon Mobil, T-Mobile US & Intuitive SurgicalZacks Investment Research
11:49AM Regeneron (REGN) Q3 Earnings Coming Up: What's in the Cards?Zacks Investment Research
Oct-31-22 06:20AM Should Invesco S&P 500 GARP ETF (SPGP) Be on Your Investing Radar?Zacks Investment Research
Oct-28-22 12:51PM Sanofi (SNY) Q3 Earnings Beat, Dupixent, Flu Jabs Push SalesZacks Investment Research
Oct-27-22 12:10PM Why Regeneron (REGN) Could Beat Earnings Estimates AgainZacks Investment Research
11:00AM Alnylam's (ALNY) Earnings and Revenues Lag Estimates in Q3Zacks Investment Research
Oct-27-22 10:02AM Regeneron (REGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research
Oct-26-22 12:07PM Biotech Stock Roundup: BIIB & BMY's Q3 Earnings, TCDA Down on Study UpdateZacks Investment Research
10:07AM Benzinga's Top Ratings Upgrades, Downgrades For October 26, 2022Benzinga
Oct-25-22 10:53AM Sanofi (SNY) to Report Q3 Earnings: What's in the Cards?Zacks Investment Research
06:50AM Biosimilars Are Revolutionizing Healthcare: Is This Industry Leader a Buy?The Motley Fool
Oct-18-22 01:20AM Roche (RHHBY) Q3 Revenues Dip on Lower COVID-19-Related SalesZacks Investment Research
09:53AM 2 Biotech Stocks You Can Buy and Hold for the Next DecadeThe Motley Fool
Oct-18-22 06:20AM Is Goldman Sachs Equal Weight U.S. Large Cap Equity ETF (GSEW) a Strong ETF Right Now?Zacks Investment Research
Oct-17-22 02:32AM Analyst Ratings for Regeneron PharmaceuticalsBenzinga
01:36AM Regeneron (REGN) Drug Gets Positive CHMP View for Cervical CancerZacks Investment Research
Oct-17-22 10:02AM Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2022Benzinga
09:13AM 13 Analysts Have This to Say About Regeneron PharmaceuticalsBenzinga
Oct-14-22 03:45AM Why Cash Rich Companies, ETFs are Beating the MarketZacks Investment Research
Oct-13-22 12:56PM Regeneron's (REGN) Eylea sBLA Gets FDA's Priority ReviewZacks Investment Research
06:30AM 3 Red-Hot Stocks That Could Continue to Beat the MarketThe Motley Fool
Oct-10-22 07:52AM Moderna, Eli Lilly And This Biotechnology Stock Insiders Are SellingBenzinga
Oct-08-22 09:35AM 2 Top Healthcare Stocks to Buy Right NowThe Motley Fool
Oct-06-22 12:49PM Tracking William Nygren's Harris Associates Portfolio - Q2 2022 UpdateSeeking Alpha
Oct-05-22 01:04AM Apple Short Sellers Made $2B In Profits In September, And Shorts In This Biotech Stock Lost $307MBenzinga
Oct-04-22 11:40AM REGN vs. RGEN: Which Stock Is the Better Value Option?Zacks Investment Research
10:23AM 3 Revolutionary Stocks I'd Buy Right Now Without HesitationThe Motley Fool
Oct-04-22 09:35AM Regeneron (REGN) Recently Broke Out Above the 20-Day Moving AverageZacks Investment Research
09:15AM Will Loss of REGEN-COV Sales Hurt Regeneron (REGN) in 2022?Zacks Investment Research
Oct-04-22 09:10AM Sanofi (SNY) Relies on Dupixent and Vaccines to Drive GrowthZacks Investment Research
08:30AM If You Invested $1000 in Regeneron 10 Years Ago, This Is How Much You'd Have NowZacks Investment Research
Oct-03-22 05:04AM 13 Analysts Have This to Say About Regeneron PharmaceuticalsBenzinga
03:38AM What 13 Analyst Ratings Have To Say About Regeneron PharmaceuticalsBenzinga
Oct-03-22 10:18AM Analyst Ratings for Regeneron PharmaceuticalsBenzinga
Sep-29-22 12:12PM Biotech Stock Roundup: BIIB's AD Drug Data & REGN, IONS, VRTX's UpdatesZacks Investment Research
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat adult patients with moderate-to-severe atopic dermatitis; Praluent injection, an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and Kevzara solution for subcutaneous injection to treat rheumatoid arthritis in adults. In addition, the company offers ARCALYST injection for cryopyrin-associated periodic syndromes; and ZALTRAP, an injection for intravenous infusion, which is used in combination with 5-fluorouracil, leucovorin, and irinotecan for the treatment of metastatic colorectal cancer. Further, it develops EYLEA, a trap-based clinical product that is in Phase III study for the treatment of neovascular glaucoma; and Dupixent, Praluent, Kevzara, Suptavumab, Cemiplimab, Fasinumab, Evinacumab, Nesvacumab/aflibercept, Trevogrumab, REGN1908-1909, REGN1979, REGN3470-3471-3479, REGN2477, REGN3500, REGN3767, and REGN3918, which are antibody-based clinical programs under various stages of development. The company has collaboration and license agreements with Sanofi, Bayer, Mitsubishi Tanabe Pharma, Teva, Intellia Therapeutics, Adicet Bio, Decibel Therapeutics, Astellas, Alnylam Pharmaceuticals, Inc., bluebird bio, Inc., and others. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.
Cap:    |  Volume (24h):